← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Equels Thomas K
Chief Executive Officer | President
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001450324
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 4
- Purchases · 24M
- 15
- Average purchase
- $9.0K
- Median purchase
- $4.8K
- Gross purchase value
- $135.3K
Companies: AIM ImmunoTech Inc.
15 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-09-18 | AIM ImmunoTech Inc. | AIM | Chief Executive Officer | President | $5.0K | Open filing |
| 2026-09-17 | AIM ImmunoTech Inc. | AIM | Chief Executive Officer | President | $2.3K | Open filing |
| 2026-09-16 | AIM ImmunoTech Inc. | AIM | Chief Executive Officer | President | $4.8K | Open filing |
| 2026-09-15 | AIM ImmunoTech Inc. | AIM | Chief Executive Officer | President | $1.3K | Open filing |
| 2025-06-16 | AIM ImmunoTech Inc. | AIM | Chief Executive Officer | President | $824 | Open filing |
| 2025-06-13 | AIM ImmunoTech Inc. | AIM | Chief Executive Officer | President | $896 | Open filing |
| 2025-04-23 | AIM ImmunoTech Inc. | AIM | Chief Executive Officer | President | $59.1K | Open filing |
| 2025-04-07 | AIM ImmunoTech Inc. | AIM | Chief Executive Officer | President | $2.5K | Open filing |
| 2025-03-06 | AIM ImmunoTech Inc. | AIM | Chief Executive Officer | President | $6.5K | Open filing |
| 2025-03-05 | AIM ImmunoTech Inc. | AIM | Chief Executive Officer | President | $5.3K | Open filing |
| 2025-03-04 | AIM ImmunoTech Inc. | AIM | Chief Executive Officer | President | $10.0K | Open filing |
| 2025-01-21 | AIM ImmunoTech Inc. | AIM | Chief Executive Officer | President | $4.2K | Open filing |
| 2024-12-19 | AIM ImmunoTech Inc. | AIM | Chief Executive Officer | President | $4.8K | Open filing |
| 2024-11-21 | AIM ImmunoTech Inc. | AIM | Chief Executive Officer | President | $17.0K | Open filing |
| 2024-11-20 | AIM ImmunoTech Inc. | AIM | Chief Executive Officer | President | $10.8K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 1/14
- Large purchase ≥ $100k
- 0/15
- Cluster buying · 15D
- 4/15
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.